Hutchison China MediTech Limited (Chi-Med) (NASDAQ:HCM) announces that its Phase 3 clinical trial, FRUTIGA,
evaluating fruquintinib, combined with Taxol (paclitaxel), in patients
with advanced gastric adenocarcinoma or gastroesophageal junction
adenocarcinoma who have progressed after first-line chemo, will continue
without modification. The action was based on a planned interim data
review by the independent Data Monitoring Committee.
Fruquintinib starves tumors of their blood supply
via inhibiting vascular endothelial growth factor receptors (VEGFR) 1, 2
& 3, which play key roles in tumor-related angiogenesis (formation
of new blood vessels).
The drug was approved in China in September 2018 and was commercially launched there by Eli Lilly (NYSE:LLY)
under the brand name Elunate for the treatment of patients with
metastatic colorectal cancer that have been previously treated with
fluoropyrimidine, oxaliplatin and irinotecan, including those who have
previously received anti-VEGF therapy and/or anti-EGFR therapy (RAS wild
type).
Chi-Med retains all rights to fruquintinib ex-China.
https://seekingalpha.com/news/3580344-late-stage-gastric-cancer-study-of-chi-meds-fruquintinib-to-continue
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.